Back to results list
Please use this identifier to cite or link to this item:
|Title:||Brevilin a induces cell cycle arrest and apoptosis in nasopharyngeal carcinoma||Authors:||Liu, R
Cell cycle arrest
|Issue Date:||2019||Publisher:||Frontiers Research Foundation||Source:||Frontiers in pharmacology, 24 May 2019, v. 10, 594, p. 1-14 How to cite?||Journal:||Frontiers in pharmacology||Abstract:||Nasopharyngeal carcinoma (NPC) is one of the most common malignant cancers in Southeast Asia and Southern China. Centipeda minima extract (CME) had previously demonstrated anti-cancer effects in human NPC. Brevilin A, a sesquiterpene lactone isolated from C. minima, has been reported to exhibit biological activities. In this study, we investigated its anti-NPC effect and further explored its molecular mechanisms. The effects of brevilin A were tested in the NPC cell lines CNE-1, CNE-2, SUNE-1, HONE1, and C666-1. Effects of brevilin A on cell viability were determined by MTT assay, and cell cycle and apoptosis were detected by flow cytometry. The molecular mechanism of cell cycle regulation and apoptosis were investigated via Western blot. Results showed that brevilin A inhibited NPC cell viability in a concentration- and time-dependent manner. Brevilin A induced cell cycle arrest at G2/M and induced apoptosis. Western blot results demonstrated that brevilin A could down-regulate cyclin D3, cdc2, p-PI3K, p-AKT, p-mTOR, and p-STAT3, while up-regulating cleaved PARP, cleaved caspase 9, and Bax. Regulation of cyclin B1, cdk6, and Bcl-2 expression by brevilin A showed dynamic changes according to dose and time. In the tumor xenograft model, brevilin A could reduce tumor growth, at a similar magnitude to cisplatin. However, notably, whereas cisplatin treatment led to significant weight loss in treated mice, treatment with brevilin A did not, indicating its relative lack of toxicity. Taken together, brevilin A regulated cell cycle, activated the caspase signaling pathway, and inhibited PI3K/AKT/mTOR and STAT3 signaling pathways in vitro, and exhibited similar efficacy to the common chemotherapeutic cisplatin in vivo, without its associated toxicity. These findings provide a framework for the preclinical development of brevilin A as a chemotherapeutic for NPC.||URI:||http://hdl.handle.net/10397/81087||EISSN:||1663-9812||DOI:||10.3389/fphar.2019.00594||Rights:||Copyright © 2019 Liu, Qu, Lin, Lee, Tai and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
The following publication Liu R, Qu Z, Lin Y, Lee C-S, Tai WC-S and Chen S (2019) Brevilin A Induces Cell Cycle Arrest and Apoptosis in Nasopharyngeal Carcinoma. Front. Pharmacol. 10:594, 14 pages is available at https://dx.doi.org/10.3389/fphar.2019.00594
|Appears in Collections:||Journal/Magazine Article|
Show full item record
Files in This Item:
|Liu_Induces_Cycle_Apoptosis.pdf||4.18 MB||Adobe PDF||View/Open|
Citations as of Nov 20, 2019
Citations as of Nov 20, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.